News

Under the agreement, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas including cardiovascular, central nervous

The study published as a research article, ‘Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes’ investigated the details of a novel proteomics based method in detecting inhibition

BOL-303259- X, a NO-donating prostaglandin F2-alpha analog, helps lower intraocular pressure (IOP) through a dual mechanism of action. The study will evaluate the most effective dose of BOL-303259-X,

The ten-year collaboration agreement will focus on translational research for innovative therapies for Alzheimer’s and Parkinson’s diseases. The Cambridge-Elan Centre will discover novel compounds capable of altering the

NVA237 is a long-acting muscarinic antagonist (LAMA) used to treat adult patients with chronic obstructive pulmonary disease (COPD). In April 2005, Novartis licensed the drug from Japan’s Sosei

Immunicum’s vaccine is based on using dendritic cells from healthy individuals and can be mass-produced, leading to commercial advantages, the company said. The study will be conducted on

LAPS-rhGH is currently being evaluated under phase II trial in patients with growth hormone deficiency in European countries. According to the company, the orphan drug designation would be

The company has been charged with, by the US Department of Justice, adulteration and mislabeling of its products, besides violation of current Good Manufacturing Practice (cGMP) regulations. ATF

AMR101 is a prescription-grade omega-3 fatty acid, consisting at least 96% ultra pure EPA (icosapent ethyl). The NDA for AMR101 is backed by data from the two Phase